Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology

Brain Pathology

Volumn 12, Issue 1, 2002, Pages 67-86

  Fuller, Christine E ^a   Perry, Arie ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TUMOR; CHROMOSOME 19Q; CHROMOSOME 1P; CONFERENCE PAPER; CONTROLLED STUDY; DNA MICROARRAY; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; OLIGODENDROGLIA;

EID: 0036133101     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2002.tb00424.x     Document Type: Conference Paper

References (203)

1. Chromosomal abnormalities in 47 pediatric brain tumors
2. Fluorescence in situ hybridization study of aneuploidy of chromosomes 7, 10, X, and Y in primary and secondary glioblastomas
3. Interphase cytogenetics reveals somatic pairing of chromosome 17 centromeres in normal human brain tissue, but no trisomy 7 or sex-chromosome loss
4. Interphase cytogenetics of brain tumors
5. Somatic pairing of chromosome 1 centromeres in interphase nuclei of human cerebellum
6. Interphase cytogenetics: A new tool for the study of genetic changes in brain tumors
7. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas
8. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
9. Advances in the detection of chromosomal aberrations using spectral karyotyping
10. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
11. Genetics of pediatric central nervous system tumors
12. Narrowing the critical region for a rhabdoid tumor locus in 22q11
13. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system
14. Germline INI1 mutation in a patient with central nervous system atypical teratoid tumor and renal rhabdoid tumor
15. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system
16. Cytogenetics of human brain tumors
17. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
18. Chromosomal characteristics of childhood brain tumors
19. Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma
20. Molecular analysis of genetic changes in ependymomas
21. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas
22. Synovial sarcoma specific translocation associated with both epithelial and spindle cell components
23. The glial and mesenchymal elements of gliosarcomas share similar genetic alteration
24. Alterations of the tumor suppressor genes CDKN2A (p16lNK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas
25. "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group study
26. A role for fluorescence in situ hybridization detection of chromosome 22q dosage in distinguishing atypical teratoid/rhabdoid tumors from medulloblastoma/central primitive neuroectodermal tumors
27. Small cell architecture: A histological equivalent of EGFR amplification in GBM?
28. Atypical teratoid/rhabdoid tumor of the central nervous system: A highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma. A Pediatric Oncology Group study
29. Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system
30. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications
31. PS6K amplification characterizes a small subset of anaplastic meningiomas
32. Successful chemotherapy for recurrent malignant oligodendroglioma
33. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
34. Validation of tissue microarray technology in breast carcinoma
35. Genetic alteration in pediatric highgrade astrocytomas
36. Pilocytic astrocytomas do not show most genetic changes commonly seen in diffuse astrocytomas
37. Investigation of genetic alterations associated with development and adverse outcome in patients with astrocytic tumor
38. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
39. Correlation of cytogenetic and fluorescence in situ hybridization (FISH) studies in normal and gliotic brain
40. Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas
41. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases
42. Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes
43. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas
44. Lissencephaly - A human brain malformation associated with deletion of the LIS1 gene located at chromosome-17p13
45. Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules
46. Molecular genetic analysis of ependymal tumors
47. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1
48. Intraneural perineurioma. A clonal neoplasm associated with abnormalities of chromosome 22
49. Prognostic factors in intracranial ependymomas in children
50. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
51. High-throughput molecular profiling of high-grade gliomas: The utility of fluorescence in situ hybridization (FISH) on tissue microarrays
52. Chromosome 22q dosage in composite extrarenal rhabdoid tumors: Clonal evolution or a phenotypic mimic?
53. Formation and detection of RNA-DNA hybrid molecules in cytological preparations
54. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers
55. Medullocytoma (lipidized medulloblastoma). A cerebellar neoplasm of adults with favorable prognosis
56. Medulloblastoma with extensive nodularity: A variant with favorable prognosis
57. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature
58. Isochromosome 17q is a constant finding in medulloblastoma. An interphase cytogenetic study on tissue sections
59. EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations
60. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
61. Chromosome abnormalities in low-grade central nervous system tumors
62. TrkC Expression predicts good clinical outcome in primitive neuroectodermal brain tumors
63. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas
64. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningioma
65. Loss of merlin expression in sporadic meningiomas, ependymomas, and schwannomas
66. Application of fluorescence in situ hybridization to detect N-myc (MYCN) gene amplification on paraffin-embedded tissue sections of neuroblastomas
67. The molecular biology of ependymomas
68. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification -associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines
69. Enhancement of hybridization efficiency in interphase cytogenetics on paraffin-embedded tissue sections by microwave treatment
70. C-MYC expression in medulloblastoma and its prognostic value
71. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups
72. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors
73. Loss of chromosome 10 in glioblastoma: Relation to proliferation and angiogenesis
74. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2
75. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
76. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma
77. Alternative EWS-FLI1 fusion gene and MIC2 expression in peripheral and central neuroectodermal tumors
78. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents
79. Mitotic recombination of chromosome 17 in astrocytomas
80. Comparative genomic hybridization as a tool in tumour cytogenetics
81. Primitive neuroectodermal tumors of the cerebrum and cerebellum: Absence of t(11;22) translocation by RT-PCR analysis
82. A cytogenetic study of 53 human gliomas
83. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization
84. RNA-DNA hybrids at the cytological level
85. Prognostic value of the expression of tumor suppressor genes p53, p21, p16, pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy
86. World Health Organization classification of tumours
87. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas
88. Tissue microarrays for high-throughput molecular profiling of tumor specimens
89. Molecular cytogenetic studies of pediatric ependymomas
90. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
91. Molecular genetic alterations in glioblastomas with oligodendroglial component
92. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas
93. Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue
94. EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression
95. Allelic losses at 1p, 9q, 10q, 14q, and 22q in sporadic meningiomas
96. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas
97. Cranial and spinal ependymomas show different molecular genetic alterations on chromosomes 11 and 22
98. The neurofibromatosis type 2 gene is mutated in perineurial cell tumors. A molecular genetic study of eight cases
99. Loss of chromosome 22q and lack of NF2 mutations in perineuriomas
100. Intramedullary spinal cord tumors in neurofibromatosis
101. Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathological and genetic features
102. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas
103. Allelic status of 1p, 14q, and 22q and NF2 gene mutation in sporadic schwannomas
104. Cancer-related gene expression profiles in NFl-associated pilocytic astrocytomas
105. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance
106. Alterations at chromosome 17 loci in peripheral nerve sheath tumors
107. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
108. Comparison of immunologic amplification vs enzymatic deposition of fluorochrome-conjugated tyramide as detection systems for FISH
109. Elevated c-myc expression in childhood medulloblastomas
110. Molecular genetic evidence for subtypes of oligoastrocytomas
111. Karyotype Studies in 18 ependymomas with literature review of 107 cases
112. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
113. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group
114. Esthesioneuroblastoma is not a member of the primitive peripheral neuroectodermal tumour-Ewing's group
115. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas
116. Tissue microarrays: What will they bring to molecular and anatomic pathology?
117. Documentation of the EWS gene rearrangements by fluorescence in situ hybridization (FISH) in frozen sections of Ewing's sarcoma-peripheral primitive neuroectodermal tumor
118. Detection of numerical karyotype changes in the giant cells of Hodgkins lymphomas by a combination of FISH and immunohistochemistry applied to paraffin sections
119. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study
120. Cytogenetics and cancer
121. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
122. Interphase cytogenetics of glioblastoma and gliosarcoma
123. Fluorescence in situ hybridization analysis with LIS1 specific probes reveals a high deletion mutation rate in isolated lissencephaly sequence
124. Oligodendroglial neoplasms: Current concepts, misconceptions, and folklore
125. Detection of p16, RB, CDK4, and p53 gene deletion / amplification by fluorescence in situ hybridization (FISH) in 96 gliomas
126. Merlin, DAL1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases
127. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: A clinicopathologic study of 53 cases
128. Cytogenetic analysis of aggressive meningiomas. Possible diagnostic and prognostic implications
129. Detection of p16 gene deletions in gliomas: Fluorescence in situ hybridization (FISH) versus quantitative PCR
130. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and MPNSTs
131. Interphase cytogenetic (in situ hybridization) detection of trisomy 21 in autopsy brains from patients with suspected Down syndrome
132. Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival formalin-fixed, paraffin-embedded tissue and light microscopy
133. A new member of the ETS family fused to EWS in Ewing tumors
134. Up-regulation of specific NF1 gene transcripts in sporadic pilocytic astrocytomas
135. Intracranial ependymomas of childhood. Long term outcome and prognostic factors
136. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas in childhood
137. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
138. PTEN gene mutations are seen in high-grade but not low-grade gliomas
139. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1
140. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma
141. Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma
142. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization
143. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
144. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma
145. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: Definition of an entity
146. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors
147. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
148. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas
149. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques
150. Analysis of pilocytic astrocytoma by comparative genomic hybridization
151. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis
152. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome
153. Signal amplification in the detection of single-copy DNA and RNA by enzyme-catalyzed deposition (CARD) of the novel fluorescent reporter substrate Cy3.29-tyramide
154. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts
155. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
156. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas: A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis
157. Tissue microarrays for gene amplification surveys in many different tumor types
158. Tyramide signal amplification (TSA)-FISH applied to mapping PCR-labeled probes less than 1 Kb in size
159. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas
160. Mixed oligoastrocytomas: A survival and prognostic factor analysis
161. Oligodendrogliomas: The Mayo Clinic experience
162. Antigen retrieval techniques: Current perspectives
163. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression
164. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients
165. Deletion of the NF2 region in both meningioma and juxtaposed meningioangiomatosis, a case report supporting a neoplastic relationship
166. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: Loss of heterozygosity for chromosome 17
167. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
168. Genetic alterations in adult diffuse glioma: Occurrence, significance, and prognostic implications
169. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
170. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers
171. PTEN mutations, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
172. Lipomatous medulloblastoma in adults. A distinct clinicopathological entity
173. Detection and amplification systems for sensitive, multiple-target DNA and RNA in situ hybridization: Looking inside cells with a spectrum of colors
174. Amplification methods to increase the sensitivity of in situ hybridization: Play CARD(S)
175. Early proliferation enhancement by monosomy 10 and intratumor heterogeneity in malignant human gliomas as revealed by smear preparations from biopsies
176. Cytogenetic abnormalities in human ependymomas
177. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
178. Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization
179. Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma
180. Karyotypes in 90 human gliomas
181. Aggressive medulloblastoma with high-level N-myc amplification
182. Peripheral primitive neuroectodermal tumors. Diagnosis, classification, and prognosis
183. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
184. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12)
185. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
186. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
187. Cytogenetic study of 33 ependymomas
188. Fluorochrome-labeled tyramides: Use in immunocytochemistry and fluorescence in situ hybridization
189. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
190. Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q
191. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma
192. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas
193. Molecular pathways in the formation of gliomas
194. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas
195. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
196. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression
197. Demystified...: Comparative genomic hybridisation
198. Cytogenetic evidence for a chromosome 22 tumor suppressor gene in ependymoma
199. Involvement of chromosome 22 in ependymomas
200. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood
201. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas
202. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations
203. Use of nonbreakpoint DNA probes to detect the t(X;18) in interphase cells from synovial sarcoma. Implications for detection of diagnostic tumor translocations